Socioeconomic aspects of incretin-based therapy
AbstractIncretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have demonstrated cardiovascular benefits in people with type 2 diabetes. However, socioeconomic disparities in their uptake may constrain the collective advantages offered by these medications to the broader population. In this review we examine the socioeconomic disparities in the utilisation of incretin-based therapies and discuss strategies to address these inequalities. Based on real-world evidence, the uptake of GLP-1 RAs is reduced in people who live in socioeconomically disadvantaged areas, have low income and educ...
Source: Diabetologia - September 3, 2023 Category: Endocrinology Source Type: research
The expanding incretin universe: from basic biology to clinical translation
AbstractIncretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1(GLP-1), potentiate meal-stimulated insulin secretion through direct (GIP + GLP-1) and indirect (GLP-1) actions on islet β-cells. GIP and GLP-1 also regulate glucagon secretion, through direct and indirect pathways. The incretin hormone receptors (GIPR and GLP-1R) are widely distributed beyond the pancreas, principally in the brain, cardiovascular and immune systems, gut and kidney, consistent with a broad array of e xtrapancreatic incretin actions. Notably, the glucoregulatory and anorectic activities of G...
Source: Diabetologia - September 3, 2023 Category: Endocrinology Source Type: research
Incretin hormones and type 2 diabetes
AbstractIncretin hormones (glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along with their derivatives they have shown therapeutic success in type 2 diabetes, with the potential for further improvements in glycaemic, cardiorenal and body weight-related outcomes. In type 2 diabetes, the incretin effect (greater insulin secretory response after oral glucose than with ‘isoglycaemic’ i.v. glucose, i.e. with an identical glycaemic stimulus) is markedly reduced or absent. This appears to be because of a reduced ability of GIP to s...
Source: Diabetologia - September 3, 2023 Category: Endocrinology Source Type: research
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
AbstractIn the last few decades, glucagon-like peptide-1 receptor (GLP-1R) agonists have changed current guidelines and improved outcomes for individuals with type 2 diabetes. However, the dual glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP-1R agonist, tirzepatide, has demonstrated superior efficacy regarding improvements in HbA1c and body weight in people with type 2 diabetes. This has led to increasing scientific interest in incretin hormones and incretin interactions, and several compounds based on dual- and multi-agonists are now being investigated for the treatment of metabolic diseases. Herein, we h...
Source: Diabetologia - September 1, 2023 Category: Endocrinology Source Type: research
Socioeconomic aspects of incretin-based therapy
AbstractIncretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have demonstrated cardiovascular benefits in people with type 2 diabetes. However, socioeconomic disparities in their uptake may constrain the collective advantages offered by these medications to the broader population. In this review we examine the socioeconomic disparities in the utilisation of incretin-based therapies and discuss strategies to address these inequalities. Based on real-world evidence, the uptake of GLP-1 RAs is reduced in people who live in socioeconomically disadvantaged areas, have low income and educ...
Source: Diabetologia - September 1, 2023 Category: Endocrinology Source Type: research
The expanding incretin universe: from basic biology to clinical translation
AbstractIncretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1(GLP-1), potentiate meal-stimulated insulin secretion through direct (GIP + GLP-1) and indirect (GLP-1) actions on islet β-cells. GIP and GLP-1 also regulate glucagon secretion, through direct and indirect pathways. The incretin hormone receptors (GIPR and GLP-1R) are widely distributed beyond the pancreas, principally in the brain, cardiovascular and immune systems, gut and kidney, consistent with a broad array of e xtrapancreatic incretin actions. Notably, the glucoregulatory and anorectic activities of G...
Source: Diabetologia - September 1, 2023 Category: Endocrinology Source Type: research
Incretin hormones and type 2 diabetes
AbstractIncretin hormones (glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along with their derivatives they have shown therapeutic success in type 2 diabetes, with the potential for further improvements in glycaemic, cardiorenal and body weight-related outcomes. In type 2 diabetes, the incretin effect (greater insulin secretory response after oral glucose than with ‘isoglycaemic’ i.v. glucose, i.e. with an identical glycaemic stimulus) is markedly reduced or absent. This appears to be because of a reduced ability of GIP to s...
Source: Diabetologia - September 1, 2023 Category: Endocrinology Source Type: research
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes
Diabetes Metab. 2023 Aug 30:101470. doi: 10.1016/j.diabet.2023.101470. Online ahead of print.ABSTRACTGlucagon-like peptide 1 (GLP-1) is a hormone of the incretin family, secreted in response to nutrient ingestion, and plays a role in metabolic homeostasis. GLP-1 receptor agonist has a peripheral and a central action, including stimulation of glucose-dependent insulin secretion and insulin biosynthesis, inhibition of glucagon secretion and gastric emptying, and inhibition of food intake. Through their mechanism, their use in the treatment of type 2 diabetes has been extended to the management of obesity, and numerous trials...
Source: Diabetes and Metabolism - September 1, 2023 Category: Endocrinology Authors: Marine Monney Fran çois R Jornayvaz Karim Gariani Source Type: research
Effects of Dipeptidyl Peptidase 4 Inhibition on the Endothelial Control of the Vascular Tone
Am J Physiol Cell Physiol. 2023 Aug 29. doi: 10.1152/ajpcell.00246.2023. Online ahead of print.ABSTRACTDipeptidyl peptidase 4 (DPP4) is a serine protease known to cleave incretin hormones, which stimulate insulin secretion after food intake, a fact that supported the development of its inhibitors (DPP4i, or gliptins) for the treatment of type 2 diabetes mellitus. In addition to their glucose lowering effects, DPP4i show benefits for the cardiovascular system that could be related, at least in part, to their protective action on the vascular endothelium. DPP4i has been associated with the reversal of endothelial dysfunction...
Source: Am J Physiol Cell Ph... - August 29, 2023 Category: Cytology Authors: Joao Carlos Ribeiro-Silva Vinicius Bermond Marques Leonardo Dos Santos Source Type: research
Effects of Dipeptidyl Peptidase 4 Inhibition on the Endothelial Control of the Vascular Tone
Am J Physiol Cell Physiol. 2023 Aug 29. doi: 10.1152/ajpcell.00246.2023. Online ahead of print.ABSTRACTDipeptidyl peptidase 4 (DPP4) is a serine protease known to cleave incretin hormones, which stimulate insulin secretion after food intake, a fact that supported the development of its inhibitors (DPP4i, or gliptins) for the treatment of type 2 diabetes mellitus. In addition to their glucose lowering effects, DPP4i show benefits for the cardiovascular system that could be related, at least in part, to their protective action on the vascular endothelium. DPP4i has been associated with the reversal of endothelial dysfunction...
Source: American Journal of Physiology. Cell Physiology - August 29, 2023 Category: Cytology Authors: Joao Carlos Ribeiro-Silva Vinicius Bermond Marques Leonardo Dos Santos Source Type: research
Effects of Dipeptidyl Peptidase 4 Inhibition on the Endothelial Control of the Vascular Tone
Am J Physiol Cell Physiol. 2023 Aug 29. doi: 10.1152/ajpcell.00246.2023. Online ahead of print.ABSTRACTDipeptidyl peptidase 4 (DPP4) is a serine protease known to cleave incretin hormones, which stimulate insulin secretion after food intake, a fact that supported the development of its inhibitors (DPP4i, or gliptins) for the treatment of type 2 diabetes mellitus. In addition to their glucose lowering effects, DPP4i show benefits for the cardiovascular system that could be related, at least in part, to their protective action on the vascular endothelium. DPP4i has been associated with the reversal of endothelial dysfunction...
Source: Atherosclerosis - August 29, 2023 Category: Cardiology Authors: Joao Carlos Ribeiro-Silva Vinicius Bermond Marques Leonardo Dos Santos Source Type: research
Effects of Dipeptidyl Peptidase 4 Inhibition on the Endothelial Control of the Vascular Tone
Am J Physiol Cell Physiol. 2023 Aug 29. doi: 10.1152/ajpcell.00246.2023. Online ahead of print.ABSTRACTDipeptidyl peptidase 4 (DPP4) is a serine protease known to cleave incretin hormones, which stimulate insulin secretion after food intake, a fact that supported the development of its inhibitors (DPP4i, or gliptins) for the treatment of type 2 diabetes mellitus. In addition to their glucose lowering effects, DPP4i show benefits for the cardiovascular system that could be related, at least in part, to their protective action on the vascular endothelium. DPP4i has been associated with the reversal of endothelial dysfunction...
Source: Am J Physiol Cell Ph... - August 29, 2023 Category: Cytology Authors: Joao Carlos Ribeiro-Silva Vinicius Bermond Marques Leonardo Dos Santos Source Type: research
Effects of Dipeptidyl Peptidase 4 Inhibition on the Endothelial Control of the Vascular Tone
Am J Physiol Cell Physiol. 2023 Aug 29. doi: 10.1152/ajpcell.00246.2023. Online ahead of print.ABSTRACTDipeptidyl peptidase 4 (DPP4) is a serine protease known to cleave incretin hormones, which stimulate insulin secretion after food intake, a fact that supported the development of its inhibitors (DPP4i, or gliptins) for the treatment of type 2 diabetes mellitus. In addition to their glucose lowering effects, DPP4i show benefits for the cardiovascular system that could be related, at least in part, to their protective action on the vascular endothelium. DPP4i has been associated with the reversal of endothelial dysfunction...
Source: American Journal of Physiology. Cell Physiology - August 29, 2023 Category: Cytology Authors: Joao Carlos Ribeiro-Silva Vinicius Bermond Marques Leonardo Dos Santos Source Type: research
Effects of Dipeptidyl Peptidase 4 Inhibition on the Endothelial Control of the Vascular Tone
Am J Physiol Cell Physiol. 2023 Aug 29. doi: 10.1152/ajpcell.00246.2023. Online ahead of print.ABSTRACTDipeptidyl peptidase 4 (DPP4) is a serine protease known to cleave incretin hormones, which stimulate insulin secretion after food intake, a fact that supported the development of its inhibitors (DPP4i, or gliptins) for the treatment of type 2 diabetes mellitus. In addition to their glucose lowering effects, DPP4i show benefits for the cardiovascular system that could be related, at least in part, to their protective action on the vascular endothelium. DPP4i has been associated with the reversal of endothelial dysfunction...
Source: Atherosclerosis - August 29, 2023 Category: Cardiology Authors: Joao Carlos Ribeiro-Silva Vinicius Bermond Marques Leonardo Dos Santos Source Type: research
Effects of Dipeptidyl Peptidase 4 Inhibition on the Endothelial Control of the Vascular Tone
Am J Physiol Cell Physiol. 2023 Aug 29. doi: 10.1152/ajpcell.00246.2023. Online ahead of print.ABSTRACTDipeptidyl peptidase 4 (DPP4) is a serine protease known to cleave incretin hormones, which stimulate insulin secretion after food intake, a fact that supported the development of its inhibitors (DPP4i, or gliptins) for the treatment of type 2 diabetes mellitus. In addition to their glucose lowering effects, DPP4i show benefits for the cardiovascular system that could be related, at least in part, to their protective action on the vascular endothelium. DPP4i has been associated with the reversal of endothelial dysfunction...
Source: Am J Physiol Cell Ph... - August 29, 2023 Category: Cytology Authors: Joao Carlos Ribeiro-Silva Vinicius Bermond Marques Leonardo Dos Santos Source Type: research
